Section of Hematology/Oncology, Department of Medicine, University of Illinois.
Ruth M. Rothstein CORE Center.
Curr Opin Infect Dis. 2024 Aug 1;37(4):254-263. doi: 10.1097/QCO.0000000000001022. Epub 2024 May 31.
Summarize the latest research of both stem cell transplantation and cellular therapy and present the implications with respect to persons with HIV (PWH), hematologic malignancies, and HIV-1 cure.
Allogeneic (alloSCT) and autologous (autoSCT) stem cell transplantation have been shown to be well tolerated and effective regardless of HIV-1 status. AlloSCT leads to a decrease in the HIV-1 latently infected reservoir orders of magnitude below that achieved with antiretroviral therapy (ART) alone. Utilization of CCR5Δ2/Δ32 donors in an alloSCT has resulted in HIV-1 cures. In the last 12 months, three cases of cure have been published, giving further insight into the conditions required for HIV-1 control. Other advances in the treatment of hematological cancers include chimeric antigen receptor T-cell (CART) therapy, which are active in PWH with lymphoma.
Here we discuss the advances in SCT and cellular therapy in PWH and cancer. Additionally, we discuss how these technologies are being utilized to achieve HIV-1 cure.
总结干细胞移植和细胞治疗的最新研究进展，并就其对人类免疫缺陷病毒（HIV）感染者（PWH）、血液系统恶性肿瘤和 HIV-1 治愈的影响进行阐述。
异体（alloSCT）和自体（autoSCT）干细胞移植已被证明耐受性良好且有效，而与 HIV-1 状态无关。alloSCT 可导致 HIV-1 潜伏感染库下降数量级，远低于单独使用抗逆转录病毒治疗（ART）。在 alloSCT 中使用 CCR5Δ2/Δ32 供体已导致 HIV-1 治愈。在过去的 12 个月中，已有三例治愈病例发表，进一步深入了解了 HIV-1 控制所需的条件。血液系统恶性肿瘤治疗的其他进展包括嵌合抗原受体 T 细胞（CART）治疗，对患有淋巴瘤的 PWH 有效。
本文讨论了 PWH 和癌症中 SCT 和细胞治疗的进展。此外，还讨论了如何利用这些技术实现 HIV-1 治愈。
